JP2005508165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508165A5 JP2005508165A5 JP2003534444A JP2003534444A JP2005508165A5 JP 2005508165 A5 JP2005508165 A5 JP 2005508165A5 JP 2003534444 A JP2003534444 A JP 2003534444A JP 2003534444 A JP2003534444 A JP 2003534444A JP 2005508165 A5 JP2005508165 A5 JP 2005508165A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- amino acids
- polynucleotide
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 96
- 108090000765 processed proteins & peptides Proteins 0.000 claims 96
- 102000004196 processed proteins & peptides Human genes 0.000 claims 96
- 150000001413 amino acids Chemical class 0.000 claims 95
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 58
- 102000040430 polynucleotide Human genes 0.000 claims 41
- 108091033319 polynucleotide Proteins 0.000 claims 41
- 239000002157 polynucleotide Substances 0.000 claims 41
- 230000014511 neuron projection development Effects 0.000 claims 24
- 102000005781 Nogo Receptor Human genes 0.000 claims 22
- 108020003872 Nogo receptor Proteins 0.000 claims 22
- 230000001404 mediated effect Effects 0.000 claims 22
- 230000005764 inhibitory process Effects 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 4
- 102000005720 Glutathione transferase Human genes 0.000 claims 4
- 108010070675 Glutathione transferase Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000016192 Demyelinating disease Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000003376 axonal effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000002569 neuron Anatomy 0.000 claims 3
- 230000008929 regeneration Effects 0.000 claims 3
- 238000011069 regeneration method Methods 0.000 claims 3
- -1 antibody Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000011403 Alexander disease Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000022526 Canavan disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims 1
- 206010056332 Panencephalitis Diseases 0.000 claims 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims 1
- 102100029826 Reticulon-4 receptor Human genes 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 230000003458 metachromatic effect Effects 0.000 claims 1
- 238000000520 microinjection Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000023105 myelination Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/972,599 US7119165B2 (en) | 2000-01-12 | 2001-10-06 | Nogo receptor-mediated blockade of axonal growth |
| PCT/US2002/032007 WO2003031462A2 (en) | 2001-10-06 | 2002-10-04 | Nogo receptor-mediated blockade of axonal growth |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508165A JP2005508165A (ja) | 2005-03-31 |
| JP2005508165A5 true JP2005508165A5 (enExample) | 2006-01-05 |
| JP4383869B2 JP4383869B2 (ja) | 2009-12-16 |
Family
ID=25519870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003534444A Expired - Fee Related JP4383869B2 (ja) | 2001-10-06 | 2002-10-04 | 軸索成長のnogoのレセプターを仲介とした妨害 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US7119165B2 (enExample) |
| EP (1) | EP1451337A4 (enExample) |
| JP (1) | JP4383869B2 (enExample) |
| AU (1) | AU2002334889B2 (enExample) |
| CA (1) | CA2461655A1 (enExample) |
| WO (1) | WO2003031462A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002522016A (ja) * | 1998-07-22 | 2002-07-23 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするcDNA |
| US7119165B2 (en) * | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| ES2341608T3 (es) * | 2000-10-06 | 2010-06-23 | Yale University | Homologos del receptor de nogo. |
| US7309485B2 (en) * | 2001-12-03 | 2007-12-18 | Children's Medical Center Corporation | Reducing myelin-mediated inhibition of axon regeneration |
| US7745151B2 (en) * | 2002-08-02 | 2010-06-29 | Children's Medical Center Corporation | Methods of determining binding between Nogo receptor and p75 neurotrophin receptor |
| ATE469913T1 (de) * | 2002-08-10 | 2010-06-15 | Univ Yale | Antagonisten des nogo-rezeptors |
| CN1745094A (zh) * | 2002-12-06 | 2006-03-08 | 新加坡综合医院有限公司 | 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途 |
| US7842666B2 (en) * | 2002-12-20 | 2010-11-30 | Research Foundation Of City University Of New York | Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration |
| PL1606409T3 (pl) | 2003-03-19 | 2011-02-28 | Biogen Ma Inc | Białko wiążące receptor Nogo |
| US7541335B2 (en) * | 2003-04-04 | 2009-06-02 | University Of Rochester | Nogo-receptors and methods of use |
| CN1832752A (zh) * | 2003-04-16 | 2006-09-13 | 耶鲁大学 | 治疗淀粉样蛋白斑相关性病症的nogo-受体拮抗剂 |
| JP2007537985A (ja) * | 2003-05-15 | 2007-12-27 | ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー | 免疫調節ペプチド |
| EA008253B1 (ru) * | 2003-08-07 | 2007-04-27 | Байоджен Айдек Ма Инк. | Антагонисты nogo-рецептора |
| CA2549000A1 (en) * | 2003-12-16 | 2005-06-30 | Children's Medical Center Corporation | Method for treating neurological disorders |
| US8912144B2 (en) * | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
| US20080045926A1 (en) * | 2004-01-30 | 2008-02-21 | Relton Jane K | Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists |
| US8039588B2 (en) * | 2004-05-21 | 2011-10-18 | The Uab Research Foundation | Variable lymphocyte receptors |
| PT1776136E (pt) * | 2004-06-24 | 2012-12-05 | Biogen Idec Inc | Tratamento de estados que envolvem desmielinização |
| EP1789070B1 (en) | 2004-08-03 | 2012-10-24 | Biogen Idec MA Inc. | Taj in neuronal function |
| CN101035803A (zh) * | 2004-10-01 | 2007-09-12 | 耶鲁大学 | Nogo-a多肽片段、变异nogo受体-1多肽、及其应用 |
| US20090010873A1 (en) * | 2004-11-29 | 2009-01-08 | Yeda Research And Development Co. Ltd. | Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis |
| EP1904091A4 (en) * | 2005-07-07 | 2009-12-23 | Univ Yale | COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH |
| SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| US20070026463A1 (en) * | 2005-07-28 | 2007-02-01 | Wyeth | Compositions and methods of mutant Nogo-66 domain proteins |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| CN101248083A (zh) * | 2005-08-25 | 2008-08-20 | 比奥根艾迪克Ma公司 | Nogo受体多肽和多肽片段及其用途 |
| CN101277974A (zh) | 2005-09-30 | 2008-10-01 | 阿伯特有限及两合公司 | 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途 |
| EP2526968A3 (en) | 2006-01-27 | 2013-05-22 | Biogen Idec MA Inc. | Nogo receptor antagonists |
| WO2007133746A2 (en) * | 2006-05-15 | 2007-11-22 | Biogen Idec Ma Inc. | Use of nogo receptor-1 (ngr1) antagonists for promoting oligodendrocyte survival |
| EP2046828A2 (en) * | 2006-07-07 | 2009-04-15 | Wyeth | Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same |
| EP2068866A4 (en) | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS |
| JP2010502623A (ja) * | 2006-08-31 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Nogoレセプターポリペプチドの末梢投与に関する方法 |
| CA2701189C (en) * | 2007-10-11 | 2017-05-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| WO2009061500A1 (en) * | 2007-11-08 | 2009-05-14 | Biogen Idec Ma Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| JP2011505010A (ja) * | 2007-11-28 | 2011-02-17 | イェール ユニバーシティー | 軸索成長を促進するNogo受容体結合低分子 |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| WO2009114197A2 (en) * | 2008-03-13 | 2009-09-17 | Yale University | Reactivation of axon growth and recovery in chronic spinal cord injury |
| EP2315779A2 (en) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
| US8580270B2 (en) | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
| PH12012501070A1 (en) | 2009-12-08 | 2017-08-23 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| AU2013211939C1 (en) | 2012-01-27 | 2018-06-07 | AbbVie Deutschland GmbH & Co. KG | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| US9796780B2 (en) | 2012-05-14 | 2017-10-24 | Biogen Ma Inc. | LINGO-2 antagonists for treatment of conditions involving motor neurons |
| WO2016112270A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250414A (en) | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
| EP0396719B1 (en) | 1988-11-04 | 1995-07-05 | Erziehungsdirektion Of The Canton Zurich | Neurite growth regulatory factors |
| CA1341050C (en) | 1988-11-04 | 2000-07-11 | Martin E. Schwab | Neurite growth regulatory factors |
| WO2000073452A2 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US5858708A (en) | 1996-08-12 | 1999-01-12 | Bandman; Olga | Polynucleotides encoding two novel human neuroendocrine-specific proteins |
| US7368531B2 (en) * | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| ES2312205T3 (es) | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
| US6962797B2 (en) * | 1998-04-15 | 2005-11-08 | Genentech, Inc. | Nucleic acids encoding PRO615 |
| CA2331154A1 (en) | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor |
| JP2002522016A (ja) | 1998-07-22 | 2002-07-23 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするcDNA |
| SK287323B6 (sk) | 1998-11-06 | 2010-07-07 | University Of Z�Rich | Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie |
| US6152155A (en) | 1998-11-30 | 2000-11-28 | Milligan; Lon | Filter cleaning device |
| KR100529270B1 (ko) | 1998-12-01 | 2005-11-21 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 |
| IL143031A0 (en) | 1998-12-22 | 2002-04-21 | Genentech Inc | Methods and compositions for inhibiting neoplastic cell growth |
| US7041474B2 (en) | 1998-12-30 | 2006-05-09 | Millennium Pharmaceuticals, Inc. | Nucleic acid encoding human tango 509 |
| KR20010103046A (ko) | 1999-03-08 | 2001-11-17 | 제넨테크, 인크. | 면역 관련 질환 치료용 조성물 및 치료 방법 |
| EP1263948A2 (en) | 1999-03-08 | 2002-12-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2004507202A (ja) | 1999-03-31 | 2004-03-11 | キュラジェン コーポレイション | ポリペプチドをコードするオープンリーディングフレームを含む核酸;「orfx」 |
| AU3632600A (en) | 1999-05-14 | 2000-12-05 | Genentech Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1268506A4 (en) | 1999-07-30 | 2004-07-28 | Millennium Pharm Inc | SECRET PROTEINS AND THEIR USE |
| US7119165B2 (en) * | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| HUP0203863A3 (en) | 2000-01-12 | 2008-03-28 | Univ Yale | Nogo receptor-mediated blockade of axonal growth |
| ES2341608T3 (es) * | 2000-10-06 | 2010-06-23 | Yale University | Homologos del receptor de nogo. |
| EP1423427A2 (en) | 2001-08-27 | 2004-06-02 | Novartis AG | Nogo receptor homologues and their use |
| WO2003035687A1 (en) | 2001-10-22 | 2003-05-01 | Novartis Ag | Nogo receptor homologues and their use |
| US7309485B2 (en) * | 2001-12-03 | 2007-12-18 | Children's Medical Center Corporation | Reducing myelin-mediated inhibition of axon regeneration |
| US20030113325A1 (en) * | 2001-12-03 | 2003-06-19 | Zhigang He | Reducing myelin-mediated inhibition of axon regeneration |
| EP1354892A1 (en) | 2002-04-19 | 2003-10-22 | Centre National De La Recherche Scientifique (Cnrs) | Peptides capable of inducing attraction of the axonal growth and their use for treating neurodegenerative diseases |
| US7745151B2 (en) * | 2002-08-02 | 2010-06-29 | Children's Medical Center Corporation | Methods of determining binding between Nogo receptor and p75 neurotrophin receptor |
| ATE469913T1 (de) | 2002-08-10 | 2010-06-15 | Univ Yale | Antagonisten des nogo-rezeptors |
| CN1832752A (zh) * | 2003-04-16 | 2006-09-13 | 耶鲁大学 | 治疗淀粉样蛋白斑相关性病症的nogo-受体拮抗剂 |
| JP2007501612A (ja) | 2003-08-07 | 2007-02-01 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Nogo受容体アンタゴニスト |
| EA008253B1 (ru) * | 2003-08-07 | 2007-04-27 | Байоджен Айдек Ма Инк. | Антагонисты nogo-рецептора |
| US20080045926A1 (en) * | 2004-01-30 | 2008-02-21 | Relton Jane K | Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists |
| WO2009114197A2 (en) | 2008-03-13 | 2009-09-17 | Yale University | Reactivation of axon growth and recovery in chronic spinal cord injury |
-
2001
- 2001-10-06 US US09/972,599 patent/US7119165B2/en not_active Expired - Lifetime
-
2002
- 2002-10-04 CA CA002461655A patent/CA2461655A1/en not_active Abandoned
- 2002-10-04 JP JP2003534444A patent/JP4383869B2/ja not_active Expired - Fee Related
- 2002-10-04 EP EP02800939A patent/EP1451337A4/en not_active Withdrawn
- 2002-10-04 AU AU2002334889A patent/AU2002334889B2/en not_active Ceased
- 2002-10-04 WO PCT/US2002/032007 patent/WO2003031462A2/en not_active Ceased
-
2006
- 2006-09-06 US US11/516,024 patent/US20080219984A1/en not_active Abandoned
-
2010
- 2010-01-26 US US12/693,940 patent/US8394929B2/en not_active Expired - Fee Related
-
2013
- 2013-03-07 US US13/788,923 patent/US20130171157A1/en not_active Abandoned
- 2013-11-22 US US14/088,158 patent/US20140178392A1/en not_active Abandoned
-
2015
- 2015-07-13 US US14/798,125 patent/US20170174763A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003519481A5 (enExample) | ||
| JP6807893B2 (ja) | α−シヌクレインを認識するヒト化抗体 | |
| KR101681910B1 (ko) | Rgm a 단백질에 대한 모노클로날 항체 및 이의 용도 | |
| ES2272093T5 (es) | Composiciones y métodos para incrementar la mineralización de la substancia ósea | |
| US9133272B2 (en) | Bispecific binding agents | |
| EP1181318B1 (en) | Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules | |
| AU2018225493B2 (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases | |
| JP2022543387A5 (enExample) | ||
| CA2872928C (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
| HRP20180516T1 (hr) | Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida | |
| JP2009520691A5 (enExample) | ||
| EA015166B1 (ru) | Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител | |
| JP2019527194A5 (enExample) | ||
| JP2008509658A5 (enExample) | ||
| RS57315B1 (sr) | Humanizovana antitela koja prepoznaju alfa-sinuklein | |
| KR20240046648A (ko) | 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법 | |
| KR20080111152A (ko) | 염증성 질환의 치료를 위한 cxcl13 길항제 및 이의 용도 | |
| JP7449859B2 (ja) | 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法 | |
| JP2020517262A5 (enExample) | ||
| JP2008509152A5 (enExample) | ||
| JPH08504086A (ja) | 背側組織作用因子及び組成物 | |
| JP2012508027A5 (enExample) | ||
| CA2750952A1 (en) | Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders | |
| RU2007146455A (ru) | Варианты эритропоэтина | |
| JP2008539745A5 (enExample) |